The effectiveness and cost of exogenous pulmonary surfactant replacement therapy
CITATION: Smith, J. Pieper, C. & Gie, R. P. 1995. The effectiveness and cost of exogenous pulmonary surfactant replacement therapy. South African Medical Journal, 85(11):1192-1196.
The original publication is available at http://www.samj.org.za
The articles"" recently published on surfactant replacement therapy (SR1) in the treatment of newborn infants with hyaline membrane disease (HMD) being ventilated in a country with limited health resources are both timeous and urgently needed. Surfactant, being an expensive drug, needs to be administered in the most costeffective fashion and for this reason research guidelines for its administration in South Africa are needed. We are concerned that the discussions of this series of articles do not sufficiently emphasise their limitations, as well as the enormous impact of SRT on survival rates and other neonatal morbidities in newborn infants ventilated with HMD.